AMENDMENTS TO THE CLAIMS

1-13 (canceled)

14. (currently amended): A method of ~~prophylaxis and/or treatment of~~ treating neuropathy, the clinical pictures and symptoms associated therewith, and related disorders comprising systemically administering an effective dose of N-methyl-N-[(1 S)-1-phenyl-2-((3 S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide, and/or a pharmaceutically acceptable derivative, solvate, salt or stereoisomer thereof, including mixtures thereof in an enteral or parenteral formulation to a subject in need thereof.

15-19. (canceled)

20. (previously presented): The method of claim 14, wherein the peripherally selective kappa-opiate agonist is N-methyl-N-[(1 S)-1-phenyl-2-((3 S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide hydrochloride.

21. (previously presented): The method of claim 14, wherein the related disorders are selected from the group consisting of post-herpetic neuralgia, vulvodynia, lupus erythematosus and chemotherapy induced neuropathy.

22. (previously presented): The method of claim 20, wherein the related disorders are selected from the group consisting of post-herpetic neuralgia, vulvodynia, lupus erythematosus and chemotherapy induced neuropathy.

23. (withdrawn): A method of treating diabetic neuropathy, comprising administering an effective dose of N-methyl-N-[(1 S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide and/or a pharmaceutically acceptable derivative, solvate, salt or stereoisomer thereof, including mixtures thereof to a subject in need thereof.

24-33. (canceled)

34. (withdrawn): The method of claim 23, wherein N-methyl-N-[(1 S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide hydrochloride is administered.

35. (withdrawn): The method of claim 23, wherein the diabetic neuropathy is painful diabetic neuropathy.

36. (withdrawn): The method of claim 34, wherein the diabetic neuropathy is painful diabetic neuropathy.

37. (currently amended): A method of treating a neuropathy related disorder, wherein the neuropathy related disorder is post-herpetic neuralgia, vulvodynia, lupus erythematosus or chemotherapy induced neuropathy, comprising systemically administering a selective opiate receptor modulator to a subject in need thereof.

38. (previously presented): The method of claim 37, wherein the selective opiate receptor modulator is N-methyl-N-[(1 S)-1-phenyl-2-((3 S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide, and/or a pharmaceutically acceptable derivative, solvate, salt or stereoisomer thereof, including mixtures thereof.

39. (previously presented): The method of claim 38, wherein the selective opiate receptor modulator is N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide hydrochloride.